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Abstract
Background: The minimal detectable change (MDC) and the minimal clinically important changes
(MCIC) have been explored for nonspecific low back pain patients and are similar across different
cultural settings. No data on MDC and MCIC for pain severity are available for neck pain patients.
The objectives of this study were to estimate MDC and MCIC for pain severity in subacute and
chronic neck pain (NP) patients, to assess if MDC and MCIC values are influenced by baseline
values and to explore if they are different in the subset of patients reporting referred pain, and in
subacute versus chronic patients.
Methods: Subacute and chronic patients treated in routine clinical practice of the Spanish National
Health Service for neck pain, with or without pain referred to the arm, and a pain severity ≥ 3
points on a pain intensity number rating scale (PI-NRS), were included in this study. Patients' own
"global perceived effect" over a 3 month period was used as the external criterion. The minimal
detectable change (MDC) was estimated by means of the standard error of measurement in
patients who self-assess as unchanged. MCIC were estimated by the mean value of change score in
patients who self-assess as improved (mean change score, MCS), and by the optimal cutoff point in
receiver operating characteristics curves (ROC). The effect on MDC and MCIC of initial scores,
duration of pain, and existence of referred pain were assessed.
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Results: 658 patients were included, 487 of them with referred pain. MDC was 4.0 PI-NRS points
for neck pain in the entire sample, 4.2 for neck pain in patients who also had referred pain, and 6.2
for referred pain. MCS was 4.1 and ROC was 1.5 for referred and for neck pain, both in the entire
sample and in patients who also complained of referred pain. ROC was lower (0.5 PI-NRS points)
for subacute than for chronic patients (1.5 points). MCS was higher for patients with more intense
baseline pain, ranging from 2.4 to 4.9 PI-NRS for neck pain and from 2.4 to 5.3 for referred pain.
Conclusion: In general, improvements ≤ 1.5 PI-NRS points could be seen as irrelevant. Above that
value, the cutoff point for clinical relevance depends on the methods used to estimate MCIC and
on the patient's baseline severity of pain. MDC and MCIC values in neck pain patients are similar
to those for low back pain and other painful conditions.
Background
Minimal detectable change (MDC) is defined as the min-
imal change that falls outside the measurement error in
the score of an instrument used to measure a symptom.
Minimal clinicall important change (MCIC) is defined as
the minimal change in the score that is meaningful for
patients [1-12]. Different approaches can be used to deter-
mine MCIC. One is to estimate the mean change in score
in patients who actually report to have improved (referred
to as "mean change score", or MCS). Another approach is
to use receiver operating characteristics curves (ROC) to
define the cutoff point that best discriminates between
patients reporting or denying any improvement. MDC,
MCS and ROC reflect different constructs, and the meth-
ods for assessing each one of them are also different.
These methods are further described in the "Methods" sec-
tion of this paper, and they lead to different values
[8,9,12].
It is useful to define MDC and MCIC for three main rea-
sons: a) to calculate the sample size of studies aiming to
assess the effectiveness or cost/effectiveness of interven-
tions, b) to interpret the clinical relevance of results in
studies on the effectiveness of treatments, and c) to help
clinicians select among treatments with slight differences
in their size effects, especially if they differ in their safety
profiles, by allowing them to anticipate the clinical mean-
ingfulness of the expected differences in their effects.
MDC and MCIC for low back pain patients have been esti-
mated in different cultural settings, with consistent results
[1-9]. In general, improvements of pain severity ≤ 1.5
points on a pain intensity numerical rating scale (PI-NRS)
could be seen as clinically irrelevant [6-9]. Above that
value, the cutoff point for "clinical relevance" depends on
patients' baseline pain severity and on the method used
for estimating it [8,9]. Results are similar in LBP patients
with and without referred pain [9]. Values for MDC and
MCIC are different across acute and chronic LBP patients,
[8] but they are stable in subacute and chronic patients
[9].
In patients with nonspecific neck pain (NP), MDC and
MCIC have been explored for disability and quality of life
[13-15]. MDC and MCIC for pain severity have also been
recently explored [16]. However, MDC and MCIC for pain
were only explored in a small sample of patients partici-
pating in a randomized controlled trial, it is unknown
whether or not they had referred pain, and approximately
75% of them were acute patients [16], while subacute and
chronic patients represent the major part of the social,
clinical and economical burden associated with spinal
disorders [17]. MCIC for neck pain might be different
between acute and chronic patients, between patients
with and without referred pain, and between patients seen
in routine clinical practice and those included in a rand-
omized controlled trial in which expectations and other
unspecific effects (such as Hawthorne or placebo) might
also influence them.
Therefore, the primary objective of this study was to calcu-
late the MDC and MCIC values for neck and referred pain
severity in subacute and chronic NP patients treated in
routine clinical practice. Additional objectives were: a) to
explore if MDC and MCIC values for neck pain were dif-
ferent in the subset of patients who reported referred pain,
b) to assess if MDC and MCIC values depended of base-
line values, and c) to explore if they were different
between subacute and chronic patients.
Methods
Setting
This study was performed in the Balearic Health Service
(Ib-Salut). The Ib-Salut is a public organization that
belongs to the Spanish National Health Service, in which
universal, tax funded health care services are provided to
every citizen. The Ib-Salut covers all of the inhabitants of
the Balearic Islands, who were about 916,500 when this
study started. All of the 515 primary care physicians work-
ing at the 49 primary care centers belonging to the Ib-Salut
were invited to participate in this study. No incentives
were offered to the physicians or patients to participate.BMC Musculoskeletal Disorders 2008, 9:43 http://www.biomedcentral.com/1471-2474/9/43
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Data from patients recruited between January 1, 2004,
and November 21, 2006, were included in this study. The
study was approved by the Medical Ethics Committees of
the participating institutions.
Study population
The study population was defined as patients seeking care
in the routine primary care practice of the Ib-Salut for sub-
acute and chronic NP, with or without referred pain.
Based on the available evidence for LBP patients, time
limits to consider a patient as "subacute" and "chronic"
were set at between 14 and 90 days, and longer than 90
days, respectively [18-20].
In accordance with the current treatment protocol for
neck pain in routine practice in the Ib-Salut, subacute and
chronic patients were referred to a specialized Unit, where
patients with a pain severity ≥ 3 points on a pain intensity
numerical rating scale (PI-NRS) [21], underwent a neu-
roreflexotherapy (NRT) intervention. This is a minimally
invasive procedure that has proven to be safe, effective
and cost/effective, and has been extensively described in
the literature [22-27]. Data included in the current study
derive from methods used for post-marketing surveillance
of this technology in routine clinical practice [22].
Inclusion criteria were: seeking health care at any of the
primary care centers belonging to the Ib-Salut, for neck
pain (NP) lasting 14 or more days, either with or without
pain referred to the arm or arms, reporting a pain severity
≥ 3 points on a pain intensity numerical rating scale (PI-
NRS) [20], and undergoing a neuroreflexotherapy (NRT)
intervention.
Exclusion criteria were [28]: data suggesting potential
underlying diseases, (the current neck pain episode being
the first one in a patient under age 20 or onset over 55 in
which appropriate diagnostic procedures had not yet been
performed before referral to the study, non-mechanical
pain, widespread neurology (disseminated neurological
findings), fever, weight loss, systemic unwellness, a his-
tory of: significant trauma, systemic steroids, osteoporo-
sis, cancer, drug abuse, HIV), widespread (>1 nerve root)
or progressive motor weakness in the arms, and patients'
refusal to sign the study's informed consent.
Outcome Assessment
The clinical condition of each patient was evaluated by the
GPs at the primary care centers, who gathered data on
duration of the current pain episode (in days); existence
of referred pain (yes/no); diagnostic procedures per-
formed in the previous 6 months, and current treatment.
Patients were assessed on their first visit (baseline assess-
ment) and three months later (12 week follow-up).
At each assessment, patients rated, on their own and with-
out assistance, two separate PI-NRS for current neck and
referred pain, ranging from "0" (no pain) to "10" (worst
imaginable pain). NP-related disability was not assessed
since no validated instrument for that purpose is available
in Spanish.
External criterion
At the 3 month follow-up, patients scored the change in
their clinical status on the following scale: 1: Completely
recovered, 2: improved, 3: unchanged, 4: worsened.
Patients rated their clinical status on their own and with-
out assistance.
Since patients graded the evolution of their own clinical
status, this classification was considered as the external
criterion for a change to be "clinically important".
Analysis
The MDC and MCIC values in the PI-NRS for neck and
referred pain were estimated for the follow-up period of 3
months.
The Minimal Detectable Change (MDC) was calculated as
1.96 * √2 * SEM. [8,12] The standard error of measure-
ment (SEM) was estimated by taking the square root of
the within subject variance (consisting of variance
between measures plus the residual variance on a two-way
ANOVA random effects model) of patients categorized as
"unchanged" by external criterion. The 95% confidence
interval was calculated using the chi-square distribution
[29]. The MDC can be interpreted as the magnitude of
change below which there is more than a 95% chance that
no real change has occurred.
The following methods were used to estimate the MCIC
[12]:
1. Mean Change Score (MCS): Mean change of PI-NRS in
patients who scored "2" ("improved") on the external cri-
terion. The changes of scores PI-NRS were calculated by
subtracting the final values from the baseline values, so
that positive scores correspond to improvement.
2. Optimal cutoff point (ROC): Considering the PI-NRS
change as a diagnostic test for discriminating between
improved and not improved patients, and the external cri-
terion as a gold standard, a ROC curve was developed
describing the performance of changes in the correspond-
ing scale to detect improvement [30]. The optimal cutoff
point was estimated by the point that maximizes the sum
of specificity and sensitivity.
Data from all recruited patients (both with and without
referred pain) were included in the main analysis, inBMC Musculoskeletal Disorders 2008, 9:43 http://www.biomedcentral.com/1471-2474/9/43
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which MDC and MCIC values for neck pain were calcu-
lated. In a subgroup analysis, only patients with referred
pain at baseline were included, and MDC and MCIC val-
ues for neck and referred pain were calculated.
The effects of baseline scores and chronicity on MDC,
MCS and ROC were estimated by defining subgroups. Val-
ues were estimated for patients with low baseline scores
(lowest tertile) and high baseline scores (highest tertile).
Values were also estimated for chronic and subacute
patients, with the cut-off point for chronicity established
at 90 days [1,30]. All statistical analyses were performed
using SPSS for Windows, version 12.0.
Results
In this study 678 patients were recruited and 20 (2.9%)
were excluded because of refusal to sign the informed con-
sent (15 cases), fever (3 cases) and patients feeling system-
atically unwell (2 cases). Therefore, 658 were included,
and none were lost to follow-up. As seen in Table 1, in
general they were middle aged working women, with
intense NP. 487 (74.0%) also reported referred pain, and
slightly over half were chronic. Twenty subjects (2.9%)
were excluded from the analysis because of missing values
corresponding to pain severity at baseline or discharge, or
on the scale corresponding to their perceived effect.
Three months later, 210 (31.9%) reported feeling com-
pletely recovered, 395 (60.0%) improved, 48 (7.3%)
unchanged, and only 5 (0.8%) worse. Table 2 shows neck
and referred pain scores at baseline and changes in scores
3 months later, for patients who reported to have "com-
pletely recovered", "improved", "not changed" or "wors-
ened".
Table 3 shows the MCIC values for neck pain estimated in
all included patients, while Table 4 shows the MCIC val-
ues for both neck and referred pain only in patients who
also reported referred pain at baseline.
As seen in those tables, MDC for neck pain is 4.0 PI-NRS
points in the entire sample and it is 4.2 for patients who
also complained from referred pain, and MDC for referred
pain is 6.2 PI-NRS points. These values are not influenced
by baseline pain severity or duration.
MCS for neck pain is 4.1 PI-NRS points, both in the entire
sample and in patients who also had referred pain, and it
is also 4.1 PI-NRS for referred pain. MCS remains constant
across subacute and chronic patients, but it is higher for
patients with more severe baseline pain. Depending on
baseline severity, MCS values range from 2.5 to 4.9 PI-
NRS points for neck pain, and from 2.4 to 5.3 for referred
pain (Tables 3 and 4).
ROC for neck pain is 1.5 PI-NRS points, ranging from 1.5
to 2.5 depending on baseline pain severity, and from 0.5
in subacute patients to 1.5 in chronic ones. Those values
for neck pain are identical in the entire sample and in
patients who also had referred pain, and they are also
identical for neck and referred pain (Tables 3 and 4).
Discussion
Results from this study show that MCIC values are similar
for neck and referred pain, and that MCIC for neck pain
Table 1: Baseline characteristics of all included patients.
Variable All included patients (N = 658) Patients with referred pain (N = 487)
Age; Mean (SD) 54.1 (14.6) 53.8 (14.2)
Gender; n (%)
Male 148 (22.5) 94 (19.3)
Female 510 (77.5) 393 (80.7)
Work status; n (%)
Active 606 (92.1) 453 (93.0)
Retired 52 (7.9) 34 (7.0)
Duration of present episode (days);
Mean (SD) 541.7 (1274.9) 580.3 (1364.8)
Chronicity:
Subacute (14–90 days) 290 (44.6) 202 (41.8)
Chronic (> 90 days) 361 (55.4) 281 (58.2)
Baseline neck pain (PI-NRS points);
N 658 485
Mean (SD) 7.2 (2.0) 7.3 (2.0)
Baseline pain referred to the arm (PI-NRS points);
N- - 4 8 7
Mean (SD) 6.6 (2.4)
PI-NRS: Pain intensity numerical rating scaleBMC Musculoskeletal Disorders 2008, 9:43 http://www.biomedcentral.com/1471-2474/9/43
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are also similar in subacute and chronic patients seen in
routine clinical practice and in the subset of those subjects
also reporting referred pain. In addition, these results sug-
gest that improvement in pain below 1.5 PI-NRS could be
seen as irrelevant, and that the cutoff point considering
change as "clinically relevant" above that value depends
on the method used to estimate MCIC and baseline sever-
ity of symptoms (Tables 3 and 4). All of those findings are
consistent with those from previous studies on low back
pain (LBP) patients [8,9]. It has been suggested that the
MCS being larger in patients with a higher baseline pain
severity is due to a smaller change potential in patients
with lower baseline scores [8,9], or to patients with more
severe pain needing to experience a greater improvement
in order to feel that it is relevant [9].
In spite of differences in methods commented on in the
Introduction section, present results are consistent with
those from the only previous study in which MDC and
ROC were explored for neck pain [16]. In that study, MDC
for neck pain was 4.3 PI-NRS points, and ROC was 2.5
[16]. In the current study, those values were 4.0 and 1.5.
In fact, the size of MDC, MCS and ROC values in this
study is similar to those found in LBP patients across stud-
ies performed with different samples in different cultural
and geographical settings [6-9]. In the current study, par-
ticipants' age and baseline pain severity for both local and
referred pain were similar to those in previous studies
with LBP patients, but 9% more women were included,
the proportion of chronic patients was 8% less, and mean
Table 2: Baseline values and final change of scores for neck pain and pain referred to the arm across different values for external 
criterion
Value Baseline neck pain1 Evolution of neck pain1 Baseline referred pain1,2,3 Evolution of referred pain1,2,3
Completely Recovered
N 210 210 142 137
Mean (SD) 6.7 (2.0) 6.1 (2.1) 6.4 (2.5) 6.0 (2.5)
Improved
N 395 395 307 304
Mean (SD) 7.4 (2.0) 4.1 (2.3) 6.7 (2.4) 4.0 (2.7)
Unchanged
N4 8 4 8 3 5 3 5
Mean (SD) 7.2 (2.1) 0.8 (1.8) 7.0 (2.2) 1.6 (2.7)
Worsened
N5 5 3 3
Mean (SD) 7.8 (1.9) -1.2 (1.6) 8.3 (0.6) -0.7 (1.5)
1: Points on a pain intensity numerical rating scale. 2: Only for patients with referred pain at baseline. 3: Positive values in change correspond to 
improvement, and negative values to worsening.
Table 3: MDC, MCS and ROC values for neck pain in all patients included in the study (with and without referred pain), and differences 
depending on baseline pain severity and chronicity





Subacute (<90 days) Chronic (≥ 90 days)
Neck pain (PI-NRS)
MDC; Value (95% CI)** 4.0 (3.4–5.0)
n4 8 1 4 2 7 1 0 3 8
MCS (SD) 4.1 (2.3) 2.6 (1.4) 4.9 (2.3) 4.1 (2.3) 4.1 (2.2)
n 395 78 209 167 223
ROC curve
Area (IC 95%) 0.92 (0.87–0.96) 0.94 (0.85–1.00) 0.95 (0.91–0.99) 0.93 (0.80–1.00) 0.91 (0.86–0.96)
Sensitivity 0.93 0.89 0.96 0.99 0.93
Specificity 0.83 0.93 0.80 0.90 0.81
ROC 1.5 1.5 1.5 0.5 1.5
N 658 164 321 290 361
PI-NRS: Pain intensity numerical rating scale.
MDC: Minimal detectable change. MCS: Mean change score. ROC: Optimal cutoff point on the ROC curve.
*: Lowest and highest tertiles do not represent the same number of patients because of repeated scores for pain severity.
1.2.1:** The low number of patients denying any change in this sample made it impossible to reliably estimate the potential effect of baseline pain 
severity and chronicity status on MDC values.BMC Musculoskeletal Disorders 2008, 9:43 http://www.biomedcentral.com/1471-2474/9/43
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duration of the current pain episode was 153 days shorter
(Table 1) [9]. In spite of those differences, in the current
study, MDC values are 4.0 PI-NRS points for neck pain
and 6.2 for referred pain (Tables 3 and 4), and corre-
sponding values in low back pain patients are similar (3.5
and 5.4 points) [9]. MDC computation relies on the
assumption of data being drawn from a normally distrib-
uted population. Although some of the subgroups
defined by chronicity or pain severity were skewed, results
for all of them are presented for completeness, and to per-
mit comparisons with results from similar studies
[8,9,16]. In this study, MCS and ROC values for neck pain
are 4.1 and 1.5 PI-NRS points (Table 3), while corre-
sponding values in low back pain patients were 4.4 and
1.5 PI-NRS [9]. Similarly, in this study MCS and ROC val-
ues for referred pain are 4.1 and 1.5 PI-NRS points (Table
4), while corresponding values for referred pain in low
back pain patients are 4.3 and 2.5 PI-NRS points [9].
Range of MCS values depending on baseline pain severity
are also consistent with those found in low back pain
patients (Tables 3 and 4) [8,9].
In general, these results are also consistent with those
from studies conducted on neck pain and on other pain-
ful conditions [10,11]. The consistency of those findings
could be interpreted as contributing to the validity of the
MDC and MCIC values deriving from the current study.
Results from this study show that ROC value for referred
pain is 1.5 PI-NRS points (Table 4), while the mean
change in PI-NRS score among patients denying any
change in that variable is 1.6 (Table 2). It may seem con-
ceptually paradoxical for ROC value to be lower than
mean change in patients denying any improvement. In
fact, this finding is due to the asymmetrical distribution of
score changes in the patients denying any improvement in
referred pain (Table 5) and, in practice, it does not affect
the validity of ROC value found in this study.
The low number of patients in this sample denying any
change made it impossible to reliably estimate the poten-
tial effect of baseline pain severity and chronicity status on
MDC values (Tables 2, 3, 4). However, results from this
Table 4: MDC, MCS and ROC values for neck pain and referred pain only in patients with referred pain at baseline, and differences 
depending on baseline pain severity and chronicity
Measurement of change Value (all 487 patients 
with referred pain at 
baseline)
Baseline pain severity (PI-NRS) Chronicity






Chronic (≥ 90 days)
Neck pain (PI-NRS)
MDC; Value (95% CI)** 4.2 (3.4–5.5)
n3 4 1 1 1 9 6 2 8
MCS (SD) 4.1 (2.3) 2.5 (1.2) 4.8 (2.4) 4.1 (2.4) 4.1 (2.3)
n 306 61 167 120 182
ROC curve
Area (IC 95%) 0.91 (0.86–0.97) 0.92 (0.80–1.00) 0.93 (0.88–0.99) 1.00 (0.99–1.00) 0.89 (0.82–0.96)
Sensitivity 0.93 0.88 0.87 0.99 0.93
Specificity 0.81 0.91 0.86 1.00 0.77
ROC 1.5 1.5 2.5 0.5 1.5
N 485 114 249 202 279
Pain referred to the 
arm (PI-NRS)
MDC; Value (95% CI)** 6.2 (5.0–8.2)
n3 5 1 1 1 9 7 3 0
MCS (SD) 4.1 (2.7) 2.4 (1.7) 5.3 (3.0) 3.7 (3.4) 3.6 (3.2)
n 304 96 127 127 193
ROC curve
Area (IC 95%) 0.81 (0.73–0.89) 0.80 (0.65–0.95) 0.86 (0.76–0.96) 0.89 (0.78–1.00) 0.76 (0.68–0.85)
Sensitivity 0.87 0.79 0.87 0.90 0.81
Specificity 0.71 0.82 0.77 0.86 0.71
ROC 1.5 1.5 2.5 0.5 1.5
N 479 159 201 214 293
PI-NRS: Pain intensity numerical rating scale
MDC: Minimal detectable change. MCS: Mean change score. ROC: Optimal cutoff point on the ROC curve.
*: Lowest and highest tertiles do not represent the same number of patients because of repeated scores for pain severity.
1.2.1:** The low number of patients denying any change in this sample made it impossible to reliably estimate the potential effect of baseline pain 
severity and chronicity status on MDC values.BMC Musculoskeletal Disorders 2008, 9:43 http://www.biomedcentral.com/1471-2474/9/43
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study show that, although MDC and MCS are different
concepts and the methods used to calculate their values
are also different, their size for neck pain is very similar
both in all the patients and in the subset of those com-
plaining from referred pain. This finding is also consistent
with results from previous studies, both in neck and low
back pain patients [8,9,16]. It might be interpreted that
the limit of what constitutes a "relevant" and a "detecta-
ble" change is similar whether it derives from the scores of
patients who report improvement or deny it. However, as
opposed to ROC, those calculations do not take into
account false positives and false negatives.
Although it is up to researchers or clinicians to decide
whether MCS or ROC are more suitable to define MCIC in
their specific circumstances, the consistency of ROC and
MCS values across studies may help them to use these
results in practice (Tables 3 and 4) [8,9,16]. The upside of
using the MCS value instead of ROC is that patients with
scores showing an improvement above its value have a
95% chance of having improved meaningfully. However,
in general, ROC might be more suitable, since scores from
patients both reporting and denying improvement are
used to calculate it, and it tends to weigh equally false-
positive and false-negative misclassifications [16]. As it
has been suggested, the choice between the two methods
may also depend on the type of intervention or the clini-
cal consequences of being a "false positive" or "false neg-
ative" [16]. For instance, some researchers may prefer to
anticipate a difference generally corresponding to ROC
(e.g. 1.5 PI-NRS points) for sample calculations in clinical
trials vs. placebo, since ROC represents "the cut-off point
that best discriminates between those patients feeling and
not feeling that they have improved" and, since its size is
smaller than MCS, it leads to larger samples. On the con-
trary, some clinicians may prefer to disregard differences
smaller than MCS (e.g., 4 PI-NRS points) when they have
to select among treatments with different safety profiles or
side effects for a given patient, since that value represents
"the mean change above which most patients would feel
they have improved".
To be included in this study, patients had to be subacute
or chronic and their pain had to be ≥ 3 PI-NRS points.
Therefore, it could be argued that this could limit the gen-
eralizability of results from the current study to patients
having pain for less than 14 days and to those with mild
pain, and future studies could estimate MCIC in them.
The positive clinical evolution of most patients in this
study made it impossible to estimate MCS and MDC for
worsening (Table 2), and that should be explored in fur-
ther studies.
Mean duration of pain when patients entered this study
was over 540 days (Table 1). During that period, they had
all received many forms of treatment and many still
received them during the study [22]. Since data being ana-
lyzed in this study derive from post-marketing surveil-
lance of neuroreflexotherapy, all of them received that
specific form of treatment [22-27]. No study has assessed
the potential influence of any specific form of treatment
on MDC or MCIC and many studies include patients
receiving heterogeneous treatments, since they are partic-
ipating in randomized controlled trials [8,16]. In fact,
MDC and MCIC calculations rely on patients' self-assess-
ment of their own evolution and scores from instruments
used to assess evolution of symptoms, no matter what
treatments are potentially influencing that evolution.
Therefore, the generalizability of results from this study
are not affected by the fact that these results derive from
the post-marketing surveillance of a particular form of
Table 5: Frequency distribution [n (%)] of change in referred pain severity according to external criterion.
Change in PI-NRS# Patients Reporting 
Complete Recovery (n = 
137)
Patients reporting 
improvement (n = 304)
Patients reporting no 
change (n = 35)
Patients reporting 
worsening (n = 3)
10 13 (9,5) 12 (3,9) 0 0
9 11 (8,0) 8 (2,6) 1 (2,9) 0
8 18 (13,1) 21 (6,9) 1 (2,9) 0
7 18 (13,1) 20 (6,6) 1 (2,9) 0
6 17 (12,4) 26 (8,6) 1 (2,9) 0
5 22 (16,1) 35 (11,5) 0 0
4 9 (6,6) 37 (12,2) 4 (11,4) 0
3 16 (11,7) 51 (16,8) 1 (2,9) 0
2 8 (5,8) 42 (13,8) 2 (5,7) 0
1 4 (2,9) 30 (9,9) 9 (25,7) 1 (33,3)
0 1 (0,7) 13 (4,3) 12 (34,3) 0
-1 0 5 (1,6) 1 (2,9) 1 (33,3)
-2 0 4 (1,3) 2 (5,7) 1 (33,3)
# Difference between baseline and final assessment scores, in PI-NRS points. Positive values reflect improvement, and negative ones worsening.BMC Musculoskeletal Disorders 2008, 9:43 http://www.biomedcentral.com/1471-2474/9/43
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treatment. The consistency of results from this study with
those from previous reports on neck pain and low back
pain patients further supports their generalizability.
In fact, using post-marketing surveillance methods in a
National Health Service to assess MCIC has a number of
advantages. It makes it possible to assess MCIC values in
routine practice conditions, as opposed to using data from
randomized controlled trials in which Hawthorne and
other unspecific effects might influence patients' percep-
tion of global improvement and, therefore, the results. In
addition, post-marketing surveillance makes it possible to
recruit large representative samples and to minimize
losses to follow-up, therefore giving a better general pic-
ture of what MCIC values are likely to be in "normal" clin-
ical conditions.
Since no validated instruments to assess neck pain-related
disability were available for Spanish speaking patients
when this study started, pain was the only symptom that
could be assessed and MCIC values for that variable were
the only ones to be calculated. Based on previous studies
in neck and low back pain patients, it is very likely that
disability also influences patients' perception of general
improvement [1-9,13,14,18,19], and further studies
should explore MCIC for that variable in this cultural
environment. However, since MCIC for pain and disabil-
ity are calculated separately [1-9], the impossibility of
assessing disability does not affect the validity of the
MCIC values for pain deriving from this study.
The use of patients' classification of their own general clin-
ical evolution as the external criterion is somewhat con-
troversial, since it requires for them to compare their
initial and final states [7,8]. However, that is how patients
assess their own evolution in routine clinical practice. It
also happens to be the usual "gold standard" for "patients'
subjective global improvement" in the research setting
[8], and has a high face validity. In routine clinical practice
it is of the utmost importance, since it would not make
sense to classify a patient as improved or deteriorated
against the patient's own personal assessment [8]. For
these reasons this was considered to be an appropriate
external criterion for the study.
In this study, patients' own classification was rated on a 4-
point scale ("completely recovered", "improved",
"unchanged" or "worsened"), [30] while other studies
have used 5 or 7-point scales to that end, in which
"improvement" and "worsening" were split into further
categories, such as "much improved", "slightly
improved", "slightly worsened" or "much worse" [1-
8,11]. However, those categories must usually be col-
lapsed at the analysis phase, so it is up to researchers to
decide how to group them. On the contrary, we preferred
for patients to rate their own evolution in the categories
that were going to be analyzed. This may have led to
patients who perceived an improvement as clinically irrel-
evant selecting the "unchanged" category. Taking into
account the objectives of this study, we find that to be suit-
able.
Conclusion
The results of this study provide a reference for what "rel-
evant" improvement means in terms of neck and referred
pain for subacute and chronic neck pain patients treated
in routine clinical practice. The values provided here may
be useful for clinicians to interpret patients' evolution
depending on the baseline severity of their symptoms and
duration of pain. They can also assist researchers in select-
ing an MCIC value depending on the context in which it
is going to be used.
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